News

To take advantage of the UK's quick medication approval procedures, the North American psychedelic drug companies Mindset, PharmAla, Mydecine, and Psyence have inked a contract with the clinical research organisation (CRO) Clerkenwell Health to test treatments for mental health...

Novavax announced that Switzerland’s Federal Office of Public Health (FOPH) and France’s Haute Autorité de Santé (HAS) have expanded their recommendations for use of Nuvaxovid™(NVX-CoV2373) as a COVID-19 booster. In Switzerland, the FOPH recommends use of Nuvaxovid as a booster...

Evaxion Biotech A/S , a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies,  announces that the Company has signed a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) for the joint...

Immix Biopharma, Inc, a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, announced patient dosing in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial. This is the fifteenth patient dosed with IMX-110 to-date. IMX-110 clinical trial...

HitGen Inc announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. , a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, which is a new class of enzymes discovered...

Kuehne+Nagel has entered into a long-term agreement for a new airside facility strategically located in the airport zone of OR Tambo International airport, Johannesburg, South Africa – the largest and busiest airport in Africa. As part of this agreement,...

Vertex Pharmaceuticals and Entrada Therapeutics, Inc. entered a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV™) therapeutics for myotonic dystrophy type 1 (DM1). The collaboration includes Entrada’s program for DM1, ENTR-701, which is in late-stage...